The USFDA has approved the use of maribavir for treating adults and pediatric patients (above 12 years) with cytomegalovirus infections that do not respond to other available drugs. Maribavir has received ‘breakthrough therapy’ and ‘priority review’ designation owing to its promising properties. It works by inhibiting the enzyme pUL97 that blocks viral replication and packaging. Cytomegaloviral (CMV) infections are most commonly caused in cell- or organ-transplant patients leading to complications and fatal consequences at times.
In order to address CMV infections that do not respond to current treatment regimens, the safety and efficacy of the maribavir were evaluated in a phase 3, multicenter, open-label, active-controlled trial. The study details are shown in Figure 1. Figure 1 . Study design Ensuring safety Maribavir can reduce the antiviral activity of cytovene and valcyte,…
